Welcome to our dedicated page for Anebulo Pharmaceuticals SEC filings (Ticker: ANEB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anebulo Pharmaceuticals, Inc. (ANEB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Anebulo is a clinical-stage pharmaceutical company developing selonabant (ANEB-001), a CB1 receptor antagonist drug candidate for acute cannabis-induced toxicity in adults and children, and its filings offer detailed insight into this development program and related corporate actions.
For ANEB, current and periodic reports such as Forms 10-K and 10-Q (when available) typically discuss research and development activities, clinical trial status for oral and intravenous selonabant, grant funding from the National Institute on Drug Abuse (NIDA), and risk factors associated with advancing a single lead product candidate. These filings also describe the company’s patent estate around selonabant and summarize its collaboration with regulators, including the U.S. Food and Drug Administration.
Form 8-K filings are particularly important for tracking material events. Recent 8-Ks describe financial results, business updates, and the company’s strategic review and going private plans. One 8-K outlines a proposed reverse stock split structure intended to reduce the number of record holders and enable deregistration and delisting, while a later 8-K reports that the Board abandoned the reverse stock split and chose instead to commence a voluntary self-tender offer to repurchase a specified number of shares at a fixed cash price per share as part of the going private strategy.
On this page, Stock Titan surfaces ANEB filings as they are posted to EDGAR and pairs them with AI-powered summaries that highlight key points, such as changes in clinical trial plans, grant awards, financing arrangements, and corporate transactions. Users can quickly scan the AI summaries for context, then open the full SEC documents for complete details on Anebulo’s operations, financial condition, and material events.
Anebulo Pharmaceuticals plans to start a cash tender offer on December 22, 2025 to buy up to 300,000 shares of its common stock at $3.50 per share, for a maximum of $1,050,000. This voluntary self-tender is part of a strategy to complete a “go private” transaction by keeping the number of stockholders below 300.
The board has decided to abandon a previously proposed reverse stock split, which would have paid $3.50 per fractional share, after activity by some holders using multiple small accounts significantly increased the expected cost. Instead, the company will proceed with the tender offer, while reserving the right to consider a reverse split or other alternatives in the future. The tender offer has not yet commenced and will proceed only under the terms described in formal offer documents that will be sent to stockholders and filed with the SEC.
Anebulo Pharmaceuticals (ANEB) reported Q1 FY2026 results with a net loss of $2,158,354 as it advances selonabant for cannabis-induced toxicity. Operating expenses were $2,260,260, with research and development at $809,991 (lower due to timing of studies) and general and administrative at $1,450,269 (higher from professional fees related to a potential going‑private transaction). Other income, net, was $101,906, aided by interest income.
Cash and cash equivalents were $10,354,773 as of September 30, 2025, and management believes this, along with availability under a $3,000,000 Loan Agreement accruing at 0.25% per annum, will fund operations for at least 12 months. No amounts were drawn under the facility. Net cash used in operating activities was $1,273,076 for the quarter.
The company received a notice of award on September 2, 2025 for Year 2 of its NIDA grant (approximately $1.0 million) to support IV selonabant development. Shares outstanding were 41,084,731 as of September 30, 2025. A Special Committee continues to evaluate strategic alternatives, including a proposed reverse stock split within a 1‑for‑2,500 to 1‑for‑7,500 range as part of a potential going‑private process.
Anebulo Pharmaceuticals, Inc. furnished an update on its business and recent financial performance. On November 13, 2025, the company issued a press release detailing its financial results for the quarter ended September 30, 2025 and providing a broader business update. That press release is attached as Exhibit 99.1 to this report and is being treated as furnished rather than filed, which limits its use for certain legal purposes under securities laws.
Anebulo Pharmaceuticals (ANEB) is seeking shareholder approval for a reverse stock split at a board-determined ratio between 1-for-2,500 and 1-for-7,500, with the Board able to set the final ratio within that range or abandon the amendment. Fractional post-split shares will be cashed out at $3.50 per pre-split share; the company estimates total cash required to retire fractional shares at approximately $4.1M assuming a 1-for-5,000 split (midpoint), with a low-end estimate of $3.2M (1-for-2,500) and high-end $4.7M (1-for-7,500). Transaction-related professional fees are estimated at $1.0M.
The proxy explains the Board and a Special Committee considered market liquidity, valuation approaches (market and income methods), a fairness opinion from Houlihan Capital, and recent affiliate purchases (private placement at $0.99 per share). As of July 11, 2025, the stock closed at $1.66, with 30‑day VWAP $1.62 and 90‑day VWAP $1.40. The company reported cash and equivalents of $13.3M and pro forma shares outstanding near 41.08M. Major holders include Aron R. English/22NW controlling over 40%–51% of shares.
Anebulo Pharmaceuticals (ANEB) filed its Form 10-K reporting 41,084,731 shares outstanding and a market value of approximately $15,057,677 based on the Nasdaq close on December 31, 2024. The company recorded an accumulated deficit of $73.9 million as of June 30, 2025 and expects to continue generating operating losses. Management states cash, cash equivalents and available funding under its Loan Agreement should fund operations for at least 12 months from issuance of the financial statements. During the year the company completed a private placement of 15,151,514 shares for gross proceeds of about $15.0 million and issued warrants exercisable at $4.215 until September 28, 2027. Grant income of $0.9 million was recognized and a Loan Agreement providing up to $10 million remains available with no balance outstanding at June 30, 2025.
Anebulo Pharmaceuticals, Inc. furnished a current report describing the release of its financial results for the quarter and fiscal year ended June 30, 2025 and a related business update. The company issued a press release on September 29, 2025 covering these results, which is included as Exhibit 99.1. The report states that this information is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act and will only be incorporated into other securities filings if specifically referenced.
Anebulo Pharmaceuticals, Inc. filed post-effective amendments to two prior Form S-8 registration statements for its 2020 Stock Incentive Plan. The earlier statements had registered 2,667,500 shares and 2,500,000 shares of common stock for issuance under the plan. With these amendments, the company is withdrawing and removing from registration all shares of common stock that were registered for the plan but remained unsold as of the amendment date. This is an administrative step that closes out the unused portion of those prior employee equity plan registrations.
Anebulo Pharmaceuticals, Inc. filed post-effective amendments to two existing Form S-8 registration statements for its 2020 Stock Incentive Plan. The amendments apply to Registration Statement No. 333-264432, which had registered 2,667,500 shares of common stock, and Registration Statement No. 333-287311, which had registered 2,500,000 shares of common stock. The company is withdrawing and removing from registration all shares of common stock that were registered for issuance under these statements but remain unsold as of the date of the filing. This step follows the company’s prior undertaking to remove any unsold shares from registration at the termination of the offering.
Anebulo Pharmaceuticals seeks stockholder approval for a reverse stock split at a ratio set within a 1-for-2,500 to 1-for-7,500 range, with the Board able to pick the exact ratio or abandon the amendment. Fractional post-split shares will be cashed out at $3.50 per share. At a midpoint 1-for-5,000 ratio, the company estimates approximately $4.1 million will be required to retire fractional shares; low and high estimates are $3.2 million and $4.7 million, respectively, plus estimated Transaction fees of about $1.0 million. The company expects to pay these amounts from cash on hand, which on March 31, 2025 included $13.3 million of cash and equivalents and $3.0 million of debt. The Special Committee obtained a fairness opinion from Houlihan Capital and noted that the $3.50 Cash Payment represents a premium to recent prices (111% to the July 11, 2025 close of $1.66; 116% to 30‑day VWAP of $1.62; 150% to 90‑day VWAP of $1.40). The proxy discloses concentrated ownership (e.g., 22NW ~40.1% and a director Aron R. English ~51.2% beneficially) and pro forma outstanding shares post-split (pro forma example: 7,980 shares after a 1-for-5,000 split).